|
Approval for the viva/brava quadripolar cardiac resynchronization therapy defibrillator (crt-d) devices and is indicated for patients who require ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life- threatening ventricular arrhythmias, for use in patients with atrial tachyarrhythmias, or those patients who are at significant risk for developing atrial tachyarrhythmias and for providing cardiac resynchronization therapy in heart failure patients on stable, optimal heart failure medical therapy if indicated, and meet any of the classifications provided in the labeling.
|
